Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)

Launched by HOSPICES CIVILS DE LYON · Jan 5, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the role of Circulating Tumor Cells (CTCs) in patients with oropharyngeal squamous cell carcinoma, a type of cancer found in the throat. Researchers want to see if measuring these cells in the blood can help predict how well patients respond to treatment and detect any early signs of the cancer coming back. The trial will involve taking blood samples at different times, such as at diagnosis and after treatment, to track changes in the number of CTCs and understand their significance.

To participate in this study, individuals must be over 18 years old and have a confirmed diagnosis of squamous cell carcinoma located in the oropharynx (the part of the throat behind the mouth). Participants should be undergoing curative treatment, which could include surgery, radiation, or chemotherapy. Throughout the trial, participants can expect to provide blood samples and receive close monitoring to see how the CTCs relate to their treatment outcomes. This study aims to enhance patient care by improving follow-up strategies and treatment management based on the findings related to CTCs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years of age
• • Squamous cell carcinoma proven on biopsy
• • Oropharyngeal location
• • Curative treatment by Surgery followed by radiotherapy (chemotherapy) Or Radiochemotherapy Or Induction chemotherapy (+/- surgery) + radiotherapy
• • Did not object to their participation in the study
• Exclusion Criteria:
• • Carcinoma of the nasopharynx, larynx, oral cavity or hypopharynx
• • Pregnant or breastfeeding woman